Mesoblast Withdraws $50 Mln From Five-Year Non-Dilutive Facility

Mesoblast Limited drew $50 million from a five-year facility provided by director and shareholder Gregory George. The financing bolsters liquidity for the commercial-stage biotech company, but the announcement is primarily a routine funding update. The news is modestly supportive and unlikely to materially move the broader market.

Analysis

Mesoblast Limited drew $50 million from a five-year facility provided by director and shareholder Gregory George. The financing bolsters liquidity for the commercial-stage biotech company, but the announcement is primarily a routine funding update. The news is modestly supportive and unlikely to materially move the broader market.